The relationship between the mean deviation slope and follow-up intraocular pressure in open-angle glaucoma patients

Journal of Glaucoma

Volumn 22, Issue 9, 2013, Pages 689-697

  Fukuchi, Takeo ^a   Yoshino, Takaiko ^a   Sawada, Hideko ^a   Seki, Masaaki ^a   Togano, Tetsuya ^a   Tanaka, Takayuki ^a   Ueda, Jun ^a   Abe, Haruki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

IOP fluctuation; mean deviation slope; mean follow up IOP; open angle glaucoma; visual field defects

Indexed keywords

ANTIGLAUCOMA AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; VISUAL FIELD DEFECT; COMPARATIVE STUDY; DISEASE COURSE; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; LOW TENSION GLAUCOMA; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PERIMETRY; PHYSIOLOGY; RETROSPECTIVE STUDY; VISION DISORDERS; VISUAL FIELD;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; VISION DISORDERS; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84890561999     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318264b779     Document Type: Article

References (56)

1. Thylefors B, Negrel AD. The global impact of glaucoma. Bull World Health Organ. 1994;72: 323-326
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90: 262-267
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-Angle glaucoma. Arch Ophthalmol. 2002;120: 701-713
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-Angle glaucoma. Arch Ophthalmol. 2002;120: 714-720
5. Leske MC, Heijl A, Hyman L, et al. Early manifest glaucoma trial: Design and baseline data. Ophthalmology. 1999;106: 2144-2153
6. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120: 1268-1279
7. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121: 48-56
8. Bengtsson B, Leske MC, Hyman L, et al. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114: 205-209
9. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-Tension group and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126: 487-497
10. Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-Tension glaucoma. Ophthalmology. 2001;108: 247-253
11. Anderson DR, Drance SM, Schulzer M. The Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal-Tension glaucoma. Am J Ophthalmol. 2003;136: 820-829
12. The Advanced Glaucoma Intervention Study Investigators. Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology. 1994;101: 1445-1455
13. The AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130: 429-440
14. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111: 1627-1635
15. Caprioli J, Coleman AL. Intraocular pressure fluctuation. A risk factor for visual field progression at low intraocular pressures in the Advance Glaucoma Intervention Study. Ophthalmology. 2008;115: 1123-1129
16. Chauhan BC, Mikelberg FS, Balaszi G, et al. Canadian Glaucoma Study, 2. Risk factors for the progression of openangle glaucoma. Arch Ophthalmol. 2008;126: 1030-1036
17. Friedman DS, Wilson MR, Liebmann JM, et al. An evidencebased assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138: S19-S31
18. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53: S3-S10
19. Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-Term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008;115: 934-940
20. Wilensky JT. The role of diurnal pressure measurements in the management of open angle glaucoma. Curr Opin Ophthalmol. 2004;15: 90-92
21. Singh K, Shrivastava A. Intraocular pressure fluctuations: How much do they matter? Curr Opinion Ophthalmol. 2009;20: 84-87
22. Stewart WC, Kolker AE, Sharpe ED, et al. Factors associated with long-Term progression or stability in primary open-Angle glaucoma. Am J Ophthalmol. 2000;130: 274-279
23. Lee PP, Walt JW, Rosenblatt LC, et al. Association between intraocular pressure variation and glaucoma progression: Data from a United States chart review. Am J Ophthalmol. 2007; 144: 901-907
24. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent factor in patients with glaucoma. J Glaucoma. 2000;9: 134-142
25. Collaer N, Zeyen T, Caprioli J. Sequential office pressure measurements in the management of glaucoma. J Glaucoma. 2005;14: 196-200
26. Spry PG, Johnson CA. Identification of progressive glaucomatous visual field loss. Surv Ophthalmol. 2002;47: 158-173
27. Mayama C, Araie M, Suzuki Y, et al. Statistical evaluation of the diagnostic accuracy of methods used to determine the progression of visual field defect in glaucoma. Ophthalmology. 2004;111: 2117-2125
28. Heijl A, Bengtsson B, Chauhan BC, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115: 1557-1565
29. Hitchings RA. Perimetry-back to the future? Br J Ophthalmol. 1994;78: 805-806
30. Casas-Llera P, Rebolleda G, Muñ oz-Negrete FJ, et al. Visual field index rate and event-based glaucoma progression analysis: Comparison in a glaucoma population. Br J Ophthalmol. 2009;93: 1576-1579
31. Holmin C, Krakau CE. Regression analysis of the central visual field in chronic glaucoma cases. A follow-up study using automatic perimetry. Acta Ophthalmol (Copenh). 1982;60: 267-274
32. McNaught AI, Crabb DP, Fitzke FW, et al. Modeling series of visual fields to detect progression in normal tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1995;233: 750-755
33. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. Savona: Italy; 2008
34. Japan Glaucoma Society. Guidelines for Glaucoma. Tokyo: Japan Glaucoma Society; 2002
35. Anderson DR, Patella VM. Automated Static Perimetry. 2nd ed. St. Louis: Mosby; 1999: 121-190
36. Fukuchi T, Yoshino T, Sawada H, et al. Progression rate of total, and upper and lower visual field defects in open-Angle glaucoma patients. Clin Ophthalmol. 2010;4: 1315-1323
37. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual field defects. Arch Ophthalmol. 1980;98: 2163-2171
38. Wilson R, Walker AM, Dueker DK, et al. Risk factors for rate of progression of glaucomatous visual field loss: A computerbased analysis. Arch Ophthalmol. 1982;100: 737-741
39. Richler M, Werner EB, Thomas D. Risk factors for progression of visual field defects in medically treated patients with glaucoma. Can J Ophthalmol. 1982;17: 245-248
40. Ishida K, Yamamoto T, Kitazawa Y. Clinical factors associated with progression of normal-Tension glaucoma. J Glaucoma. 1998;7: 372-377
41. Daugeliene L, Yamamoto T, Kitazawa Y. Risk factors for visual field damage progression in normal-Tension glaucoma eyes. Graefes Arch Clin Exp Ophthalmol. 1999;237: 105-108
42. Suzuki Y, Shirato S, Adachi M, et al. Risk factors for the progression of treated primary open-Angle glaucoma: A multivariate life-Table analysis. Graefes Arch Clin Exp Ophthalmol. 1999;237: 463-467
43. Chen PP, Park RJ. Visual field progression in patients with initially unilateral visual field loss from chronic open-Angle glaucoma. Ophthalmology. 2000;107: 1688-1692
44. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-Tension glaucoma. Am J Ophthalmol. 2001;131: 699-708
45. Tezel G, Siegmund KD, Trinkaus K, et al. Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol. 2001;119: 813-818
46. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol. 2003;48: S3-S8
47. Allingham RR, Damji K, Freedman S, et al. (eds). Management of the glaucoma patients. Shields' Textbook of Glaucoma. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 437-445
48. Singh K, Shrivastava A. Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care. Surv Ophthalmol. 2008;53: S33-S38
49. Hitchings RA, Wu J, Poinoosawmy D, et al. Surgery for normal-Tension glaucoma. Br J Ophthalmol. 1995;79: 402-406
50. Daugeliene L, Yamamoto T, Kitazawa Y. Effect of trabeculectomy on visual field in progressive normal-Tension glaucoma. J Glaucoma. 1998;42: 286-292
51. Shigeeda T, Tomidokoro a, Araie M, et al. Long-Term followup of visual field progression after trabeculectomy in progressive normal-Tension glaucoma. Ophthalmology. 2002; 109: 766-770
52. Sit A, Asrani S. Effects of medications and surgery on intraocular pressure fluctuation. Surv Ophthalmol. 2008;53: S45-S55
53. Konstas AG, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-Angle glaucoma. Ophthalmology. 2006;113: 761-765
54. Stewart WC, Konstas AG, Nelson LA, et al. Meta-Analysis of 24 - hours intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115: 1117-1122
55. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41: 2566-2573
56. Cantor L. Achieving low target pressure with today's glaucoma medications. Surv Ophthalmol. 2003;48: S8-S16